Literature DB >> 10556756

Salivary duct carcinoma: an unusual case of long-term evolution.

B Madrigal1, J García, J C De Vicente.   

Abstract

Salivary duct carcinoma is a highly malignant adenocarcinoma of salivary origin. Its pathologic features are distinct from the other salivary gland tumors and bear a remarkable histologic resemblance to ductal breast carcinoma. The clinical course is rapid and the prognosis is dismal. Aggressive therapy is warranted, including primary tumor resection, cervical neck dissection, and radiotherapy. We present a case of salivary duct carcinoma of parotid origin with a very long-term evolution in clear contrast to its supposed aggressiveness. Tumor cells expressed low- and high-molecular-weight cytokeratins, epithelial membrane antigen, carcinoembryonic antigen, and c-erbB-2 but not estrogen and progesterone receptors, actin, and S-100.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556756     DOI: 10.1016/s1079-2104(99)70092-2

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  4 in total

1.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

2.  Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour.

Authors:  A Etges; D S Pinto; L P Kowalski; F A Soares; V C Araújo
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

3.  Locally advanced salivary duct carcinoma of the parotid gland.

Authors:  Ashwin Kallianpur; Rajni Yadav; Nootan K Shukla; S V S Deo; Dilip K Muduly
Journal:  Ann Maxillofac Surg       Date:  2012-07

4.  Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.

Authors:  Saúl Campos-Gómez; Jose H Flores-Arredondo; Rita Dorantes-Heredia; Mónica Chapa-Ibargüengoitia; Roberto de la Peña-Lopez
Journal:  BMC Cancer       Date:  2014-09-23       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.